Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer

Molecular Cancer Therapeutics

Volumn 7, Issue 10, 2008, Pages 3275-3284

  Song, Dongweon ^a   Chaerkady, Raghothama ^b,f   Tan, Aik Choon ^a   García García, Elena ^d   Nalli, Anuradha ^b,f   Suárez Gauthier, Ana ^d   López Ríos, Fernando ^d   Xian, Feng Zhang ^a   Solomon, Anna ^a   Tong, Jeffrey ^e   Read, Margaret ^e   Fritz, Christian ^e   Jimeno, Antonio ^a   Pandey, Akhilesh ^b,c   Hidalgo, Manuel ^a,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Hospital Madrid Norte Sanchinarro   (Spain)

^e Infinity Pharmaceuticals Inc   (United States)

^f Institute of Bioinformatics   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CALM1 PROTEIN; FAM84B PROTEIN; FDPS PROTEIN; GOLPH2 PROTEIN; HBA1 PROTEIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HIST1H1C PROTEIN; HLA B ANTIGEN; HSPA 1B PROTEIN; LGALS3 PROTEIN; MARCKS PROTEIN; PROTEIN DERIVATIVE; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM; TANESPIMYCIN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHALATIONAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEOMICS; TUMOR GROWTH; UPREGULATION; XENOGRAFT; AMINO ACID SEQUENCE; CELL PROLIFERATION; CHEMISTRY; DNA MICROARRAY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MASS SPECTROMETRY; METABOLISM; MOLECULAR GENETICS; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BLOTTING, WESTERN; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION PROFILING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LACTAMS, MACROCYCLIC; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PROTEOMICS; SIGNAL TRANSDUCTION; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 55749110744     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0508     Document Type: Article

References (47)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Janes RH, Jr., Niederhuber JE, Chmiel JS, et al. National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg 1996;223:261-72.
3. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72; discussion -3.
4. Welch WJ. Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev 1992;72:1063-81.
5. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet 1988; 22:631-77.
6. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
7. Miyata Y. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 2005;11:1131-8.
8. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-50.
9. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75.
10. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17- demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42:273-9.
11. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
12. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L. 17AAG: low target binding affinity and potent cell activity - finding an explanation. Mol Cancer Ther 2003;2:123-9.
13. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-93.
14. Pacey S, Banerji U, Judson I, Workman P. Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 2006;172:331-58.
15. Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006;103:17408-13.
16. Zhang H, Chung D, Yang YC, et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006;5:1256-64.
17. Schlecht NF, Burk RD, Adrien L, et al. Gene expression profiles in HPV-infected head and neck cancer. J Pathol 2007;213:283-93.
18. Maloney A, Clarke PA, Naaby-Hansen S, et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2007;67:3239-53.
19. Clarke PA, Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000;19:4125-33.
20. Seike M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007;99:1257-69.
21. Gan CS, Chong PK, Pham TK, Wright PC. Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J Proteome Res 2007;6:821-7.
22. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-61.
23. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
24. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
25. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24.
26. Notarnicola M, Messa C, Cavallini A, et al. Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology 2004;67:351-8.
27. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002;35:1431-40.
28. Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005;43:1007-12.
29. Ozbek N, Birinci A, Karaoglanoglu O, et al. HLA alleles and lung cancer in a Turkish population. Ann Saudi Med 2004;24:106-11.
30. Lavado R, Benavides M, Villar E, Ales I, Alonso A, Caballero A. The HLA-B7 allele confers susceptibility to breast cancer in Spanish women. Immunol Lett 2005;101:223-5.
31. Oerke S, Hohn H, Zehbe I, et al. Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer. Int J Cancer 2005;114:766-78.
32. Yamano T, Murata S, Shimbara N, et al. Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing. J Exp Med 2002;196:185-96.
33. Ungefroren H, Groth S, Ruhnke M, Kalthoff H, Fandrich F. Transforming growth factor-β (TGF-β) type I receptor/ALK5-dependent activation of the GADD45β gene mediates the induction of biglycan expression by TGF-β. J Biol Chem 2005;280:2644-52.
34. Ahmed H, Banerjee PP, Vasta GR. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun 2007;358:241-6.
35. Weinberger PM, Adam BL, Gourin CG, et al. Association of nuclear, cytoplasmic expression of galectin-3 with β-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2007;133: 503-10.
36. Lee JW, Song SY, Choi JJ, et al. Decreased galectin-3 expression during the progression of cervical neoplasia. J Cancer Res Clin Oncol 2006;132:241-7.
37. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998; 94:471-80.
38. Guo F, Rocha K, Bali P, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005;65:10536-44.
39. Kim TS, Jang CY, Kim HD, Lee JY, Ahn BY, Kim J. Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation. Mol Biol Cell 2006;17:824-33.
40. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93.
41. Yin X, Zhang H, Burrows F, Zhang L, Shores CG. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2005;11: 3889-96.
42. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-13.
43. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006;75:271-94.
44. Eiseman JL, Lan J, Lagattuta TF, et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[(2-dimethylamino)ethyl]amino]-geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 2005;55:21-32.
45. Newcomb EW, Lukyanov Y, Schnee T, et al. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo. Anticancer Drugs 2007;18: 875-82.
46. Banerji U, Sain N, Sharp SY, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol 2008;62:769-78.
47. Williams CR, Tabios R, Linehan WM, Neckers L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol 2007; 178:1528-32.